AIDOT launched “Cerviray,” a machine-learning-based AI solution for cervical cancer.

Whenever AIDOT improves its in-house AI algorithm, it evaluates the software (SW) quality through the Telecommunications Technology Association (TTA). Through this process, it has been recognized for excellent quality, with 93% sensitivity and 89% specificity. Based on these results, the company obtained domestic GMP Grade 3 certification, and it has formally submitted a clinical plan to pursue KFDA Grade 3 certification, entering the certification process.

AIDOT has completed a mutual business cooperation agreement with a domestic medical foundation. Once MFDS certification is completed in early next year, the company plans to apply the solution immediately at primary care hospitals that have expressed an intention to adopt it.

As a result of active marketing in the global market, AIDOT signed additional contracts in India and South America, among other regions. In particular, it was selected for the “Bio Health Worldwide Online 2020” program run by the Seoul Metropolitan Government and KOTRA, and after conducting intensive conferences with partners from a total of 17 countries, it achieved tangible market-entry results.

In addition, through a specialized overseas expansion program of the National IT Industry Promotion Agency (NIPA), interest from a Vietnamese national healthcare company—in a market where AIDOT has already entered—has been strong, leading to further joint research and additional steps toward a formal contract.

Published: November 26, 2020 / ETNews / Reporter Kim Ji-seon